Active OCS

Phase 3Small molecule

GSK

Active OCS is one of 15 small molecule programs targeting Hypereosinophilic syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypereosinophilic SyndromeActive, not recruiting

Hypereosinophilic SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Hypereosinophilic Syndrome

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Approved

1 2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Fasenra

2 4

Nucala

GGlaxo Dba Glaxosmithkline

Phase 3

6 5

EXDENSUR

GGlaxo Dba Glaxosmithkline

Phase 3

1 6

Gleevec

Novartis

Phase 2

3 7

Jakafi

Incyte

Phase 2

2 8

Cinqair

Teva

Phase 2

—9

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

1 10

Gleevec

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypereosinophilic syndrome1 trial

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

Completed· GSK logo

GSK·Phase 3·NCT02836496·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Active OCS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Active OCS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Active OCS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

Active OCS

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypereosinophilic syndrome1 trial

References

Drug Info

Quick Facts

Related News